8 Questions on Lung Cancer

Article

Do you know what percentage of lung cancer patients present with intracranial metastases? Or the most common renal abnormality seen in the presence of lung cancer? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is A. Adenocarcinoma

Question 2:

Answer and Question 3 on Next Page »

The correct answer is D. PET scan

Question 3:

Answer and Question 4 on Next Page »

The correct answer is C. Radiotherapy is usually not an effective treatment for palliative management in SCLC

Question 4:

Answer and Question 5 on Next Page »

The correct answer is A. Nephrotic syndrome

Question 5:

Answer and Question 6 on Next Page »

The correct answer is B. 10%

Question 6:

Answer and Question 7 on Next Page »

The correct answer is A. Trousseau syndrome

Question 7:

Answer and Question 8 on Next Page »

The correct answer is E. TTF1

Question 8:

Answer on Next Page »

The correct answer is B. Non-squamous NSCLC

 

Recent Videos
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer

Jonah Feldman
October 20th 2025
Article

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

Chris Ryan
October 19th 2025
Article

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Sirexatamab Combo Shows Efficacy in DKK1-High Metastatic CRC Subgroups

Tony Berberabe, MPH
October 19th 2025
Article

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial

Kristi Rosa
October 19th 2025
Article

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.